SCHEMBL3597098

SCHEMBL3597098

CN(CCNC(=O)Cn1cnc2cc(Cl)ccc21)C1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
POLB P06746 2/20 0.42
BACE1 P56817 2/20 0.41
TRPA1 O75762 2/20 0.40
LMNA P02545 2/20 0.40
HPGD P15428 2/20 0.39
PRPS1 P60891 1/20 0.39
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
CDK5 Q00535 1/20 0.38
MAPK1 P28482 1/20 0.38
CTSD P07339 1/20 0.38
KCNH2 Q12809 1/20 0.38
BACE2 Q9Y5Z0 1/20 0.38
TP53 P04637 2/20 0.38
MAPT P10636 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13115367 0.92 TRPA1 (0.42) KMT2AMEN1POLBBACE1TRPA1
SCHEMBL3602186 0.89 TP53 (0.41) KMT2AMEN1POLBTRPA1HPGD
SCHEMBL3605821 0.88 CCNE1 (0.43) KMT2AMEN1POLBHPGDPRPS1
SCHEMBL3606205 0.87 TP53 (0.45) KMT2AMEN1HPGDALDH1A1SMN1; SMN2
SCHEMBL3599700 0.86 ATM (0.42) KMT2AMEN1POLBTRPA1LMNA
SCHEMBL5345349 0.83 TRPA1 (0.43) KMT2APOLBTRPA1LMNAALDH1A1
SCHEMBL3597093 0.81 BACE1 (0.47) KMT2AMEN1POLBBACE1TRPA1
SCHEMBL5367265 0.81 MTNR1A (0.52) ALDH1A1TP53MAPTL3MBTL1
SCHEMBL3608391 0.81 GAA (0.42) KMT2AMEN1TRPA1LMNAPRPS1
SCHEMBL13115590 0.80 ATM (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 KMT2A 3838/4885MEN1 4362/4885POLB 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.